Copy the molecule, scale the manufacturing, compete on cost
5 Market outlook Eli Lillys oral non-peptide GLP-1RA orforglipron is advancing through the ACHIEVE Phase III program, with Lilly signaling regulatory submissions for obesity in 2025 and type 2 diabetes in 2026, following positive results from both Phase 2 obesity (GZGI) and Phase 3 T2DM (ACHIEVE-1) trials
doi: 10.1158/1541-7786.MCR-11-0156
*Correspondence: Alessandro Pocai, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Metabolism Support Berberine Patch: A plant-powered patch designed to support a healthy lifestyle and daily balance
You know, those ads are a reflection of the number of people out there who have come to depend on these drugs, people like Phil, the chemistry teacher whose insurance kicked him off Ozempic while he was still struggling with food and drug addictions
